MedPageToday -- BOSTON -- Chewable tablets containing the integrase inhibitor raltegravir appear to help children ages 2 to 5 control HIV even after previous regimens have failed to keep the virus in check, a small study showed. After 24 weeks of treatment, about 71% of the young patients achieved a successful response to treatment -- a decline of at least 1 log10 or approximately 90% in circulating copies of HIV, said Sharon Nachman, MD, professor of pediatrics at Stony Brook University Medical Center in New York, at her poster presentation during the annual Conference on Retroviruses and Opportunistic Infections.
